Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

16:40 EDT 6th May 2016 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models

Immunotherapy with antibodies targeting the amyloid-β peptide has yet to show any cognitive benefit in Alzheimer's disease patients in clinical trials. In vivo two-photon imaging in mouse models of A...

Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology

Alzheimer's Association awards $4.3 million to accelerate the launch of new drug treatment

(Alzheimer's Association) The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit known as DIAN-TU Next Gene...

ALZHEIMER: Le Bexarotène ou l'espoir d'un traitement efficace? - Science Advances

La question est posée avec le bexarotène « suspecté » de pouvoir prévenir la maladie d'Alzheimer avant même l'apparition des symptômes. Ce...

Alzheimer’s Disease and Diabetes Mellitus

Alzheimer’s Disease and Diabetes Mellitus Larry H. Bernstein, MD, FCAP, Curator LPBI   Unraveling Alzheimer’s:Making Sense of the Relationship between Diabetes and Alzheimer’s Disease1 ...

Alzheimer funding analyzer launched on Journal of Alzheimer's Disease website

(IOS Press) The Journal of Alzheimer's Disease (JAD) is proud to announce the launch of the Alzheimer's Funding Analyzer (AFA) on the JAD website. It is a free service that is part of a new suite of o...

Role of infectious agent in Alzheimer’s Disease?

Role of infectious agent in Alzheimer’s Disease? Larry H. Bernstein, MD, FCAP, Curator LPBI   Role of Infection in Alzheimer’s Ignored, Experts Say Nancy A. Melville   http://www.me...

ALZHEIMER: Mais pourquoi le patient ne reconnait-il plus ses proches? - Journal of Alzheimer's Disease

Les patients atteints d'Alzheimer peuvent encore ressentir des émotions et avoir une vie affective, même après la perte de la mémoire et du souvenir des proches. Cette &eacu...

Matching PubMed Articles

Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease.

Cathepsin D (CatD) is a lysosomal protease that is elevated early in Alzheimer's disease (AD). We have previously developed a Targeted contrast agent (CA) to detect CatD activity in vivo, consisting o...

In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease.

Only 5% of the Alzheimer's cases are explained by genetic mutations, whereas the remaining 95% are sporadic. The pathophysiological mechanisms underlying sporadic Alzheimer's disease are not well unde...

Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies.

Alzheimer's disease (AD) has traditionally been considered a disease of the gray matter (GM). However, several pathological and neuroimaging studies provided evidence of white matter (WM) abnormalitie...

Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.

The Arizona Alzheimer's Consortium (AAC) created the Arizona Alzheimer's Registry, a screening and referral process for people interested in participating in Alzheimer's disease related research. The ...

Understanding Aspects of aluminum exposure in Alzheimer's disease development.

Aluminum is a ubiquitously abundant non-essential element. Aluminum has been associated with neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, and dialysis encepha...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement